All In Biotech

Drug Trial Radar · NCT05470114

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

A Randomized, Double-blinded, Active Comparator-controlled, 16-week, Single-site, Exploratory, Mechanistic Trial to Assess the Effect of LEO 138559 on the Molecular Signature and Safety in Adults With Moderate to Severe Atopic Dermatitis.

Last checked: Nov 20, 2026Latest source record: Mar 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

13

Actual

Start

May 19, 2022

Primary completion

Jun 7, 2023

Study completion Oct 9, 2023

Sponsor

Lead sponsor
LEO PharmaIndustry
Sponsor type
Industry
First posted
Jul 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial will investigate the effectiveness and safety of a new active ingredient (LEO 138559) in the treatment of moderate to severe atopic dermatitis (AD). It is given by subcutaneous injection. Some people in the trial will instead receive Dupixent® which is an approved treatment for moderate to severe AD. Dupixent® is also given by subcutaneous injection. The main aim of this clinical trial is to investigate which changes in biomarkers in the skin are caused by LEO 138559 and Dupixent®. The trial includes a screening phase of up to 4 weeks, followed by a treatment period of 16 weeks, and a safety follow-up period of 16 weeks.

Conditions

  • Atopic Dermatitis

Interventions

  • LEO 138559Drug

    LEO 138559 is an antibody given by subcutaneous injection.

  • Dupixent®Drug

    Dupixent® is an antibody given by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Gene Expression Typically Associated With Atopic Dermatitis in Lesional Skin Biopsies From Baseline to Week 4Time frame: From baseline to week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • LEO Investigational Site

    Vienna, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.